The Role of Filgotinib in Ulcerative Colitis and Crohn’s Disease

STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD

Turner, D., Ricciuto, A., Lewis, A., D’Amico, F., Dhaliwal, J., Griffiths, A. M., Bettenworth, D., Sandborn, W. J., Sands, B. E., Reinisch, W., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.12.031 · Cited by 2,911 · see citing works

The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017

Alatab, S., Sepanlou, S. G., Ikuta, K., Vahedi, H., Bisignano, C., Safiri, S., Sadeghi, A., Nixon, M. R., Abdoli, A., Abolhassani, H., et al. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30333-4 · Cited by 2,313 · see citing works

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

Feagan, B. G., Sandborn, W. J., Gasink, C., Jacobstein, D., Lang, Y., Friedman, J. R., BLANK, M. A., Johanns, J., Gao, L.-L., Ye, M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602773 · Cited by 1,851 · see citing works

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

Sandborn, W. J., Su, C. G., Sands, B. E., D’Haens, G., Vermeire, S., Schreiber, S., Danese, S., Feagan, B. G., Reinisch, W., Niezychowski, W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606910 · Cited by 1,783 · see citing works

The JAK-STAT Pathway at Twenty

Stark, G. R., & Darnell, J. E., Jr. (2012) · Immunity · doi:10.1016/j.immuni.2012.03.013 · Cited by 1,523 · see citing works

ECCO guidelines on therapeutics in Crohn's disease: medical treatment

Torres, J., Bonovas, S., Doherty, G., Kucharzik, T., Gisbert, J. P., Raine, T., Adamina, M., Armuzzi, A., Bachmann, O., Bager, P., et al. (2020) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjz180 · Cited by 1,374 · see citing works

Pathophysiology of Inflammatory Bowel Diseases

Chang, J. T. (2020) · New England Journal of Medicine · doi:10.1056/nejmra2002697 · Cited by 1,295 · see citing works

JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects

Banerjee, S., Biehl, A., Gadina, M., Hasni, S., & Schwartz, D. M. (2017) · Drugs · doi:10.1007/s40265-017-0701-9 · Cited by 1,206 · see citing works

Colorectal Cancer in Inflammatory Bowel Disease: Mechanisms and Management

Shah, S. C., & Itzkowitz, S. H. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.10.035 · Cited by 849 · see citing works

Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials

Danese, S., Vermeire, S., Zhou, W., Pangan, A. L., Siffledeen, J. S., Greenbloom, S., Hébuterne, X., D’Haens, G., Nakase, H., Panés, J., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00581-5 · Cited by 653 · see citing works

JAK–STAT pathway targeting for the treatment of inflammatory bowel disease

Salas, A., Hernández-Rocha, C., Duijvestein, M., Faubion, W. A., McGovern, D. P. B., Vermeire, S., Vetrano, S., & Casteele, N. V. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0273-0 · Cited by 646 · see citing works

Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment

Axelrad, J. E., Lichtiger, S., & Yajnik, V. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i20.4794 · Cited by 467 · see citing works

Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial

Feagan, B. G., Danese, S., Loftus, E. V., Vermeire, S., Schreiber, S., Ritter, T. E., Fogel, R., Mehta, R. M., Nijhawan, S., Kempiński, R., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00666-8 · Cited by 466 · see citing works

Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial

Vermeire, S., Schreiber, S., Petryka, R., Kuehbacher, T., Hebuterne, X., Roblin, X., Klopocka, M., Goldis, A., Wisniewska-Jarosinska, M., Baranovsky, A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32537-5 · Cited by 439 · see citing works

Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis

Lasa, J. S., Olivera, P. A., Danese, S., & Peyrin‐Biroulet, L. (2021) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(21)00377-0 · Cited by 391 · see citing works

Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials

Panés, J., Sandborn, W. J., Schreiber, S., Sands, B. E., Vermeire, S., D’Haens, G., Panaccione, R., Higgins, P., Colombel, J., Feagan, B. G., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-312735 · Cited by 374 · see citing works

JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib

Través, P. G., Murray, B. P., Campigotto, F., Galien, R., Meng, A., & Paolo, J. A. D. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-219012 · Cited by 357 · see citing works

Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis

Olivera, P. A., Lasa, J. S., Bonovas, S., Danese, S., & Peyrin‐Biroulet, L. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.001 · Cited by 336 · see citing works

Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease

Coskun, M., Salem, M. A., Pedersen, J., & Nielsen, O. H. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2013.06.007 · Cited by 327 · see citing works

Systematic review with meta‐analysis: the efficacy of a second anti‐ TNF in patients with inflammatory bowel disease whose previous anti‐ TNF treatment has failed

Gisbert, J. P., Marín, A. C., McNicholl, A. G., & Chaparro, M. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13083 · Cited by 321 · see citing works

A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease

Sandborn, W. J., Ghosh, S., Panés, J., Vranic, I., Wang, W., Niezychowski, W., Vermeire, S. A. R. A., Dewit, O., Peeters, H., Stehlik, J., et al. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.01.029 · Cited by 300 · see citing works

Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement

Nash, P. T., Kerschbaumer, A., Dörner, T., Dougados, M., Fleischmann, R., Geissler, K. H., McInnes, I. B., Pope, J. E., van der Heijde, D. M. F. M., Stoffer, M. A., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-218398 · Cited by 300 · see citing works

Ulcerative Colitis and Crohn’s Disease Have Similar Burden and Goals for Treatment

Berre, C. L., Ananthakrishnan, A. N., Danese, S., Singh, S., & Peyrin‐Biroulet, L. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.07.005 · Cited by 244 · see citing works

Prognostic Factors for Advanced Colorectal Neoplasia in Inflammatory Bowel Disease: Systematic Review and Meta-analysis

Wijnands, A. M., de Jong, M. E., Lutgens, M. W. M. D., Hoentjen, F., Elias, S. G., & Oldenburg, B. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.12.036 · Cited by 241 · see citing works

Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases

Rompaey, L. V., Galien, R., van der Aar, E. M., Clément-Lacroix, P., Nelles, L., Smets, B., Lepescheux, L., Christophe, T., Conrath, K., Vandeghinste, N., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201348 · Cited by 235 · see citing works

Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis

Singh, S., George, J., Boland, B. S., Casteele, N. V., & Sandborn, W. J. (2018) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjy004 · Cited by 233 · see citing works

Formation of STAT1-STAT2 Heterodimers and Their Role in the Activation of IRF-1 Gene Transcription by Interferon- (*)

Li, X., Leung, S., Qureshi, S. A., Darnell, J., & Stark, G. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.10.5790 · Cited by 231 · see citing works

Breaking the therapeutic ceiling in drug development in ulcerative colitis

Alsoud, D., Verstockt, B., Fiocchi, C., & Vermeire, S. (2021) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(21)00065-0 · Cited by 217 · see citing works

The Impact of Carboxylesterases in Drug Metabolism and Pharmacokinetics

Di, L. (2018) · Current Drug Metabolism · doi:10.2174/1389200219666180821094502 · Cited by 211 · see citing works

Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis

Ahmed, W., Galati, J. S., Kumar, A., Christos, P. J., Longman, R., Lukin, D. J., Scherl, E., & Battat, R. J. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.03.034 · Cited by 200 · see citing works

Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme

Sandborn, W. J., Panés, J., Sands, B. E., Reinisch, W., Su, C. G., Lawendy, N., Koram, N., Fan, H., Jones, T. V., Modesto, I., et al. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15514 · Cited by 169 · see citing works

Selective JAK inhibitors in development for rheumatoid arthritis

Norman, P. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.918604 · Cited by 157 · see citing works

JAK selectivity for inflammatory bowel disease treatment: does it clinically matter?

Danese, S., ARGOLLO, M. C., Berre, C. L., & Peyrin‐Biroulet, L. (2019) · Gut · doi:10.1136/gutjnl-2019-318448 · Cited by 149 · see citing works

Defining the difference: What Makes Biologics Unique.

Morrow, T., & Felcone, L. H. (2004) · Europe PMC (PubMed Central) · Cited by 148 · see citing works

STAT proteins: a kaleidoscope of canonical and non-canonical functions in immunity and cancer

Awasthi, N. P., Liongue, C., & Ward, A. C. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01214-y · Cited by 146 · see citing works

Differential Associations between the Cytoplasmic Regions of the Interleukin-12 Receptor Subunits β1 and β2 and JAK Kinases

Zou, J., Presky, D. H., Wu, C. Y., & Gubler, U. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.9.6073 · Cited by 139 · see citing works

Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection

Namour, F., Diderichsen, P. M., Cox, E. H., Vayssière, B., der Aa, A. V., Tasset, C. T., & Klooster, G. A. E. V. '. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0240-z · Cited by 138 · see citing works

Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance

Kristensen, L. E., Danese, S., Yndestad, A., Wang, C., Nagy, E., Modesto, I., Rivas, J. L., & Benda, B. (2023) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2022-223715 · Cited by 130 · see citing works

Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis

Mohamed, M. F., Camp, H. S., Jiang, P. X., Padley, R. J., Asatryan, A., & Othman, A. A. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0419-y · Cited by 117 · see citing works

Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition

Dowty, M. E., Lin, T. H., Jesson, M. I., Hegen, M., Martin, D. A., Katkade, V., Menon, S. S., & Telliez, J. (2019) · Pharmacology Research & Perspectives · doi:10.1002/prp2.537 · Cited by 114 · see citing works

Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis

Sands, B. E., Taub, P. R., Armuzzi, A., Friedman, G. S., Moscariello, M., Lawendy, N., Pedersen, R. D., Chan, G. L., Nduaka, C. I., Quirk, D. M., et al. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.04.059 · Cited by 113 · see citing works

Targeting S1P in Inflammatory Bowel Disease: New Avenues for Modulating Intestinal Leukocyte Migration

Danese, S., Furfaro, F., & Vetrano, S. (2017) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjx107 · Cited by 94 · see citing works

Review article: immunogenicity of anti‐TNF biologics in IBD – the role of patient, product and prescriber factors

Moss, A. C., Brinks, V., & Carpenter, J. F. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12507 · Cited by 89 · see citing works

JAK inhibition in inflammatory bowel disease

Olivera, P. A., Danese, S., & Peyrin‐Biroulet, L. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1291342 · Cited by 89 · see citing works

Positioning Therapies in Ulcerative Colitis

Danese, S., Fiorino, G., & Peyrin‐Biroulet, L. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.01.017 · Cited by 83 · see citing works

Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models

Cornejo, M., Kharas, M. G., Werneck, M. B. F., Bras, S. L., Moore, S. A., Ball, B. J., Beylot-Barry, M., Rodig, S. J., Aster, J. C., Lee, B. H., et al. (2009) · Blood · doi:10.1182/blood-2008-06-164368 · Cited by 82 · see citing works

Review article: emerging drug therapies in inflammatory bowel disease

Grossberg, L. B., Papamichael, K., & Cheifetz, A. S. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16785 · Cited by 77 · see citing works

Tyrosine kinase 2 is not limiting human antiviral type III interferon responses

Fuchs, S. P., Kaiser‐Labusch, P., Bank, J., Ammann, S., Kolb‐Kokocinski, A., Edelbusch, C., Omran, H., & Ehl, S. R. (2016) · European Journal of Immunology · doi:10.1002/eji.201646519 · Cited by 75 · see citing works

Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials

D’Amico, F., Fiorino, G., Furfaro, F., Allocca, M., & Danese, S. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1492547 · Cited by 72 · see citing works

Catching the Therapeutic Window of Opportunity in Early Crohn’s Disease

Danese, S., Fiorino, G., Fernandes, C., & Peyrin‐Biroulet, L. (2014) · Current Drug Targets · doi:10.2174/1389450115666140908125738 · Cited by 68 · see citing works

Filgotinib: A Clinical Pharmacology Review

Namour, F., Anderson, K., Nelson, C., & Tasset, C. T. (2022) · Clinical Pharmacokinetics · doi:10.1007/s40262-022-01129-y · Cited by 61 · see citing works

Clinical Confirmation that the Selective JAK1 Inhibitor Filgotinib (GLPG0634) has a Low Liability for Drug-drug Interactions

Namour, F., Desrivot, J., der Aa, A. V., Harrison, P., Tasset, C. T., & Klooster, G. A. E. V. '. (2016) · Drug Metabolism Letters · doi:10.2174/1872312810666151223103353 · Cited by 55 · see citing works

Inhibition of JAK2 Suppresses Myelopoiesis and Atherosclerosis in Apoe−/− Mice

Tang, Y., Liu, W., Wang, W., Fidler, T. P., Woods, B., Levine, R. L., Tall, A. R., & Wang, N. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-06943-9 · Cited by 54 · see citing works

Declining Rates of Surgery for Inflammatory Bowel Disease in the Era of Biologic Therapy

Lowe, S. C., Sauk, J. S., Limketkai, B. N., & Kwaan, M. R. (2020) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-020-04832-y · Cited by 52 · see citing works

Efficacy, Safety and Future Perspectives of JAK Inhibitors in the IBD Treatment

Dudek, P., Fabisiak, A., Zatorski, H., Malecka-Wojciesko, E., & Talar‐Wojnarowska, R. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10235660 · Cited by 44 · see citing works

Patients with inflammatory bowel disease (IBD) prefer oral tablets over other modes of medicine administration

Denesh, D., Carbonell, J., Kane, J. S., Gracie, D. J., & Selinger, C. P. (2021) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1898944 · Cited by 42 · see citing works

Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme

Winthrop, K. L., Loftus, E. V., Baumgart, D. C., Reinisch, W., Nduaka, C. I., Lawendy, N., Chan, G. L., Mundayat, R., Friedman, G. S., Salese, L., et al. (2020) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjaa233 · Cited by 42 · see citing works

Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis

D’Amico, F., Magro, F., Peyrin‐Biroulet, L., & Danese, S. (2021) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjab206 · Cited by 37 · see citing works

MANTA and MANTA-RAy: Rationale and Design of Trials Evaluating Effects of Filgotinib on Semen Parameters in Patients with Inflammatory Diseases

Hellstrom, W. J. G., Dolhain, R. J. E. M., Ritter, T. E., Watkins, T. R., Arterburn, S., Dekkers, G., Gillen, A., Tonussi, C., Gilles, L., Oortwijn, A. F., et al. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02168-4 · Cited by 36 · see citing works

Defining Failure of Medical Therapy for Inflammatory Bowel Disease

Volk, N. R., & Siegel, C. A. (2018) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izy238 · Cited by 34 · see citing works

Role of the combination of biologics and/or small molecules in the treatment of patients with inflammatory bowel disease

Balderramo, D. C. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i47.6743 · Cited by 33 · see citing works

Rapid and Sustained Symptom Relief in Patients With Ulcerative Colitis Treated With Filgotinib: Data From the Phase 2b/3 SELECTION Trial

Danese, S., Ferrante, M., Feagan, B. G., Peyrin‐Biroulet, L., Hibi∥, T., Sandborn, W. J., Schreiber, S., Ritter, T. E., Loftus, E. V., Rogler, G., et al. (2022) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001979 · Cited by 33 · see citing works

Evaluating Upadacitinib in the Treatment of Moderate-to-Severe Active Ulcerative Colitis: Design, Development, and Potential Position in Therapy

Napolitano, M., D’Amico, F., Ragaini, E. M., Peyrin‐Biroulet, L., & Danese, S. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s340459 · Cited by 30 · see citing works

Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor

Namour, F., Fagard, L., der Aa, A. V., Harrison, P., Xin, Y., & Tasset, C. T. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13726 · Cited by 30 · see citing works

Herpes Zoster and Vaccination Strategies in Inflammatory Bowel Diseases: A Practical Guide

Guillo, L., Rabaud, C., Choy, E., D’Amico, F., Danese, S., Ng, S. C., & Peyrin‐Biroulet, L. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.10.027 · Cited by 29 · see citing works

Multidisciplinary Team-Based Approaches to IBD Management: How Might “One-Stop Shopping” Work for Complex IBD Care?

Lee, C. K., & MELMED, G. Y. (2017) · The American Journal of Gastroenterology · doi:10.1038/ajg.2017.124 · Cited by 28 · see citing works

The Relative Bioavailability and Effects of Food and Acid‐Reducing Agents on Filgotinib Tablets in Healthy Subjects

Anderson, K., Zheng, H. W., Kotecha, M., Cuvin, J., Scott, B., Sharma, S., Qin, A., Namour, F., & Xin, Y. (2019) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.659 · Cited by 21 · see citing works

Risk minimization of JAK inhibitors in ulcerative colitis following regulatory guidance

Danese, S., Solitano, V., Jairath, V., & Peyrin‐Biroulet, L. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00722-7 · Cited by 21 · see citing works

A scoping review on early inflammatory bowel disease: definitions, pathogenesis, and impact on clinical outcomes

Estevinho, M. M., Leão Moreira, P., Silva, I., Laranjeira Correia, J., Santiago, M., & Magro, F. (2022) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848221142673 · Cited by 18 · see citing works

Advances in pharmacotherapy for ulcerative colitis: a focus on JAK1 inhibitors

Goetsch, A., D’Amico, F., Allocca, M., Fiorino, G., Furfaro, F., Zilli, A., Parigi, T. L., Radice, S., Peyrin‐Biroulet, L., & Danese, S. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2200931 · Cited by 17 · see citing works

Network meta‐analysis on efficacy and safety of different Janus kinase inhibitors for ulcerative colitis

Li, Y., Yao, C., Qin, X., Xie, F., Luo, L., Li, T., & Feng, P. (2022) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13622 · Cited by 16 · see citing works

Lack of Drug‐Drug Interaction Between Filgotinib, a Selective JAK1 Inhibitor, and Oral Hormonal Contraceptives Levonorgestrel/Ethinyl Estradiol in Healthy Volunteers

Begley, R., Anderson, K., Watkins, T. R., Weng, W., Ampaw, L., Qin, A., Kearney, B. P., & Mathias, A. A. (2020) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.870 · Cited by 14 · see citing works

Publisher Correction: Crohn’s disease

Roda, G., Ng, S. C., Kotze, P. G., ARGOLLO, M. C., Panaccione, R., Spinelli, A., Kaser, A., Peyrin‐Biroulet, L., & Danese, S. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0172-2 · Cited by 10 · see citing works

Filgotinib for moderately to severely active ulcerative colitis

Mannucci, A., D’Amico, F., Saadi, A. E., Peyrin‐Biroulet, L., & Danese, S. (2022) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2022.2138857 · Cited by 9 · see citing works

JAK inhibitors in crohn’s disease: ready to go?

Dell’Avalle, C., D’Amico, F., Gabbiadini, R., Buono, A. D., Pugliese, N., Zilli, A., Furfaro, F., Fiorino, G., Allocca, M., Peyrin‐Biroulet, L., et al. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2032639 · Cited by 7 · see citing works

Critical Appraisal of Filgotinib in the Treatment of Ulcerative Colitis: Current Evidence and Place in Therapy

Buono, A. D., Gabbiadini, R., Solitano, V., Vespa, E., Parigi, T. L., Repici, A., Spinelli, A., & Armuzzi, A. (2022) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s350193 · Cited by 6 · see citing works

OP07 Exploring disease control by combining clinical, biological, and health-related quality of life remission with endoscopic improvements among Ulcerative Colitis patients treated with filgotinib: A post-hoc analysis from the SELECTION trial

Schreiber, S., Feagan, B. G., Peyrin‐Biroulet, L., Vermeire, S., Faes, M., Harris, K., Oortwijn, A. F., Daniele, P., Patel, H., & Danese, S. (2022) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjab232.006 · Cited by 5 · see citing works

P491 Efficacy and safety outcomes of long-term treatment with filgotinib 200 mg among patients with Ulcerative Colitis: An interim analysis of SELECTIONLTE

Officer, B. G. F. S. S., Matsuoka, K., Rogler, G., Faes, M., Oortwijn, A. F., de Haas, A., Rudolph, C., Patel, H., & Peyrin‐Biroulet, L. (2022) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjab232.618 · Cited by 5 · see citing works

DOP37 Efficacy and safety of filgotinib in patients with Ulcerative Colitis stratified by age: Post hoc analysis of the phase 2b/3 SELECTION and SELECTIONLTE studies

Schreiber, S., Loftus, E. V., Maaser, C., Danese, S., Rudolph, C., Jongen, R., Haas, A. D., Oortwijn, A. F., & Vermeire, S. (2022) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjab232.076 · Cited by 5 · see citing works

The double-edged effects of IL-6 in liver regeneration, aging, inflammation, and diseases

Wang, M.-J., Zhang, H.-L., Chen, F., Guo, X.-J., Liu, Q.-G., & Hou, J. (2024) · Experimental Hematology & Oncology · doi:10.1186/s40164-024-00527-1 · Cited by 84 · see citing works

Goblet cells: guardians of gut immunity and their role in gastrointestinal diseases

Tonetti, F. R., Eguileor, Á., & Llorente, C. (2024) · eGastroenterology · doi:10.1136/egastro-2024-100098 · Cited by 54 · see citing works

Real-World Effectiveness and Safety of Selective JAK Inhibitors in Ulcerative Colitis and Crohn’s Disease: A Retrospective, Multicentre Study

Farkas, B., Bessissow, T., Limdi, J. K., Sethi-Arora, K., Валерьевна, К. А., Knyazev, O. V., Bezzio, C., Armuzzi, A., Lukáš, M., Michalopoulos, G., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13247804 · Cited by 19 · see citing works

Game changer: How Janus kinase inhibitors are reshaping the landscape of ulcerative colitis management

Caballero-Mateos, A. M., & la Fuente, G. A. C. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i35.3942 · Cited by 15 · see citing works

Targeting mucosal healing in Crohn’s disease: efficacy of novel pathways and therapeutic targets

Centanni, L., Bencardino, S., D’Amico, F., Zilli, A., Parigi, T. L., Allocca, M., Danese, S., & Furfaro, F. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2433124 · Cited by 12 · see citing works

Fibroblast Heterogeneity in Inflammatory Bowel Disease

Ke, B.-J., Dragoni, G., & Matteoli, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252313008 · Cited by 8 · see citing works

Targeting Interferon‐Gamma (IFN‐γ)‐Related Signalling Pathways in Inflammatory Bowel Disease: Emerging Inhibitors and Therapeutic Advances

Rahaman, M. M., Wangchuk, P., & Sarker, S. (2025) · Mediators of Inflammation · doi:10.1155/mi/3181200 · Cited by 8 · see citing works

Small Molecule Therapy for Inflammatory Bowel Disease: JAK Inhibitors and S1PR Modulators

Jun, Y. K., & Yoon, H. (2024) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2024.064 · Cited by 8 · see citing works

The Significance of STAT3 in Colonic Diseases: A Comprehensive Study of Pathological Roles and Therapeutic Implications

Ahmed, A. T., Oghenemaro, E. F., Hjazi, A., Jain, V. D., Ahmad, I., Roopashree, R., Soothwal, P. K., Goswami, M., Zwamel, A. H., & Kdhim, K. (2025) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-025-01816-0 · Cited by 4 · see citing works

JAK inhibitor ameliorates inflammatory bowel disease in a patient with IKZF1 haploinsufficiency

Inoue, S., Ikai, M., Nambu, R., Moriya, K., Kojima, R., Tagami, Y., Hoshino, Y., Kyushiki, M., Ichimura, K., Nakazawa, A., et al. (2025) · Clinical Immunology · doi:10.1016/j.clim.2025.110470 · Cited by 4 · see citing works

Challenges and Treatment Strategies in Elderly Patients with Inflammatory Bowel Disease: A Systematic Review and Narrative Synthesis

Triantafillidis, J. K., Malgarinos, K., Kontrarou, G., Kritsotakis, E., Polydorou, V., Pantos, K., Sfakianoudis, K., Pantou, A., Karandreas, A., Konstandoulakis, M., et al. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16020059 · Cited by 2 · see citing works

Expanding the therapeutic horizon in inflammatory bowel disease: The rise of non-cytokine compounds

Prado, Á. D., García-Alonso, F. J., Arribas‐Rodríguez, E., Barrio, J., Gisbert, J. P., & Bernardo, D. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119401 · Cited by 2 · see citing works

Updated review of Janus kinase inhibitors for the management of inflammatory bowel disease

Malakar, S., Giri, S., Jena, A., & Nath, P. (2026) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v17.i1.112788 · Cited by 1 · see citing works

Role of Janus kinase-signal transducer and activator of transcription signaling pathway in hormonal cancer therapeutic resistance and lineage plasticity

Effah, W., Khalil, M., Sukla, S., Zhao, C., Ponnusamy, S., Pfeffer, L. M., Choi, H. Y., & Narayanan, R. (2026) · Endocrinology · doi:10.1210/endocr/bqag035

Recent advances in the discovery of small-molecule inhibitors for inflammatory bowel disease therapy

Lin, H., Wen, S., Huang, Y., & Wang, S. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119080

Novel Therapeutic Strategies and Biomarkers in the Management of Inflammatory Bowel Disease: A Narrative Review

Kandathil, Z., Raihan, A., & Mathanaruban, T. (2026) · Cureus · doi:10.7759/cureus.113698

Critical Appraisal of Filgotinib in the Treatment of Ulcerative Colitis: Current Evidence and Place in Therapy

Buono, A. D., Gabbiadini, R., Solitano, V., Vespa, E., Parigi, T. L., Repici, A., Spinelli, A., & Armuzzi, A. (2022) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s350193 · Cited by 6 · see citing works

Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis

D’Amico, F., Magro, F., Peyrin‐Biroulet, L., & Danese, S. (2021) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjab206 · Cited by 37 · see citing works

Filgotinib for the treatment of Crohn’s disease

Labetoulle, R., Paul, S., & Roblin, X. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1442433 · Cited by 15 · see citing works

S1926 Efficacy of Filgotinib in Patients With Ulcerative Colitis: A Systemic Review and Meta-Analysis

Karaveetil, S. C., Bellur, V. C., Prasad, A., Oudit, O., Mohan, T. C., Magaji, R. R., Giri, A., Gupta, A. K., Naidu, K. B. B., Alva, A. N., et al. (2025) · The American Journal of Gastroenterology · doi:10.14309/01.ajg.0001135164.55920.de

Filgotinib for moderately to severely active ulcerative colitis

Mannucci, A., D’Amico, F., Saadi, A. E., Peyrin‐Biroulet, L., & Danese, S. (2022) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2022.2138857 · Cited by 9 · see citing works